Compare Stocks

→ Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEXO HEXO	$0.71 +2.5%	$0.87	$0.66 ▼ $3.84	$31.24M	1.35	880,508 shs	305,500 shs
HLS HLS Therapeutics	C$4.73 -0.4%	C$4.31	C$3.34 ▼ C$7.12	C$150.98M	1.16	9,501 shs	4,512 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HEXO HEXO	0.00%	0.00%	0.00%	0.00%	-38.79%
HLS HLS Therapeutics	-0.42%	-3.86%	+31.02%	+15.65%	-18.17%

The Hard Truth About Investing For Retirement (Ad)

Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.

Click To Access This Powerful Training Right Now!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HEXO HEXO	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HLS HLS Therapeutics	0.0735 of 5 stars	1.1	0.0	1.7	0.0	0.6	0.8	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HEXO HEXO	N/A	N/A	N/A	N/A
HLS HLS Therapeutics	2.25	Hold	C$4.58	-3.28% Downside

Current Analyst Ratings

Latest HLS, HEXO, and EOF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/18/2024	HLS HLS Therapeutics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target		C$6.50 ➝ C$5.00
3/15/2024	HLS HLS Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target		C$4.35 ➝ C$4.15
2/22/2024	HLS HLS Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target		C$5.00 ➝ C$4.35
2/6/2024	HLS HLS Therapeutics	Clarus Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HEXO HEXO	$146.20M	0.21	N/A	N/A	$2.44 per share	0.29
HLS HLS Therapeutics	C$63.07M	2.39	C$0.31 per share	15.22	C$3.06 per share	1.55

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HEXO HEXO	-$845.90M	-$5.21	N/A	N/A	N/A	-235.33%	-74.04%	-32.51%	N/A
HLS HLS Therapeutics	-C$27.53M	-C$1.16	N/A	∞	N/A	-43.65%	-24.69%	-2.87%	5/9/2024 (Estimated)

Latest HLS, HEXO, and EOF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/14/2024	Q4 2023	HLS HLS Therapeutics	-C$0.13	-C$0.18	-C$0.05	-C$0.13	C$21.83 million	C$21.60 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HEXO HEXO	N/A	N/A	N/A	N/A	N/A
HLS HLS Therapeutics	C$0.20	4.23%	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HEXO HEXO	0.01	0.41	0.24
HLS HLS Therapeutics	89.69	1.65	1.01

Ownership

Institutional Ownership

Company	Institutional Ownership
HEXO HEXO	7.78%
HLS HLS Therapeutics	59.62%

Insider Ownership

Company	Insider Ownership
HEXO HEXO	4.69%
HLS HLS Therapeutics	0.49%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
HEXO HEXO	1,277	44.00 million	41.93 million	Optionable
HLS HLS Therapeutics	91	31.92 million	N/A	Not Optionable

HLS, HEXO, and EOF Headlines

Source	Headline
	Branching Regulatory Paths and Dead Ends in Psychedelics theregreview.org - April 15 at 1:53 AM
	Who Is Cara Mund? Former Miss America Who Supports Abortion Rights Announces Run for US House as Republican in North Dakota ibtimes.sg - April 10 at 12:16 AM
	HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference finance.yahoo.com - April 9 at 8:27 AM
	Cara Mund running for US House in North Dakota Republican primary bismarcktribune.com - April 8 at 5:55 PM
	New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups finance.yahoo.com - April 8 at 7:31 AM
	Getting to Yes, And…\| Elaine Lin Hering – Unlearning Silence wgnradio.com - April 2 at 10:55 AM
	Earnings Release: Here's Why Analysts Cut Their HLS Therapeutics Inc. (TSE:HLS) Price Target To CA$6.57 finance.yahoo.com - March 17 at 10:03 AM
	HLS has price target cut at Raymond James cantechletter.com - March 15 at 8:14 PM
	HLS Therapeutics Inc. (TSE:HLS) stock most popular amongst retail investors who own 40%, while hedge funds hold 39% finance.yahoo.com - March 14 at 12:41 PM
	HLS Therapeutics Announces Fiscal 2023 Financial Results finance.yahoo.com - March 14 at 7:34 AM
	HLS Therapeutics earnings: here's what to expect markets.businessinsider.com - March 13 at 10:32 AM
	Amicus Curiae Returning to Campus marshallparthenon.com - February 21 at 1:11 PM
	Several Insiders Invested In HLS Therapeutics Flagging Positive News finance.yahoo.com - February 21 at 1:11 PM
	Stocks in play: HLS Therapeutics Inc. ca.finance.yahoo.com - February 6 at 1:07 PM
	HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan finance.yahoo.com - February 6 at 7:35 AM
	Jennifer J. Raab named President and CEO of The New York Stem Cell Foundation eurekalert.org - January 31 at 10:48 PM
	Pharma breakthroughs: 10 novel drug approvals that made headlines in 2023 msn.com - December 20 at 11:16 AM
	HLS Therapeutics CFO Tim Hendrickson to Step Down marketwatch.com - December 18 at 7:58 AM
	HLS Therapeutics appoints John Hanna as interim CFO msn.com - December 18 at 7:58 AM
	HLS Therapeutics Announces CFO Departure finance.yahoo.com - December 18 at 7:58 AM
	2 Top Pharmaceutical Stocks to Buy on the TSX Today msn.com - December 11 at 7:41 PM
	Cerebral venous thrombosis should be considered in a postpartum patient with headache and seizure cmaj.ca - December 11 at 9:41 AM
	Some HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's Estimates finance.yahoo.com - November 15 at 7:05 AM
	New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline finance.yahoo.com - November 14 at 5:47 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

HEXO

NYSE:HEXO

HEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.

HLS Therapeutics

TSE:HLS

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial